Virtual Meeting 4:00 PM
Co-Hosted with The Petrie-Flom Center For Bioethics at Harvard University
Human challenge trials for COVID-19 offer an opportunity to speed the development of treatments and vaccines that can help tame the pandemic. But they are risky for participants, and pose thorny ethical questions. Even with willing volunteers, the scientific and medical communities must carefully weigh the risks before launching any human challenge trials, and put strong ethical safeguards in place.
Join Duke Science & Society and our panel of experts in a discussion of the science, promise, and risks of human challenge trials, how they might play a role in bringing an end to the coronavirus pandemic, and how to legally and ethically do so.
Dr. Marc Lipstich,Harvard School of Public Health, Department of Epidemiology & Department of Immunology and Infectious Disease; Director, Center for Communicable Disease Dynamics
Dr. Nir Eyal, Rutgers University, Henry Rutgers Professor of Bioethics; Director of The Center for Population-Level Bioethics (CPLB); Department of Health Behavior, Society, and Policy
Kim Krawiec, J.D. Duke University School of Law, Kathrine Robinson Everett Professor of Law
As we practice social distancing, engage in online learning, and work remotely we are burdened with questions about how this pandemic is affecting our lives, the lives of those we love, and the society we are a part of. Over the course of this event series faculty and staff from Duke Science and Society will join academics, lawmakers, students, researchers, doctors, and others to shed some light on the events happening around us and what life will start to look like moving forward.
We will have moderated, casual lunch-time discussions with brief Q&A held via Zoom chat.